Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene

Area of Science:

• Cardiology
• Molecular Biology
• Oncology

Background:

• Anthracyclines are vital chemotherapy agents but can cause irreversible cardiomyopathy.
• Anthracycline treatment induces cardiomyocyte apoptosis and autophagy, contributing to heart damage.
• The role of microRNAs, specifically miR-223-3p, and their targets in this process remains incompletely understood.

Purpose of the Study:

• To elucidate the molecular mechanism by which miR-223-3p influences anthracycline-induced cardiomyocyte damage.
• To investigate the relationship between miR-223-3p and nuclear factor I-A (NFIA) in AC16 cells.
• To determine the therapeutic potential of targeting miR-223-3p in mitigating chemotherapy-induced heart damage.

Main Methods:

• Utilized AC16 cells and anthracycline treatment to model chemotherapy-induced cardiomyopathy.
• Employed miR-223-3p mimics to assess its effect on NFIA expression.
• Performed knockdown of miR-223-3p to evaluate its impact on apoptosis and autophagy.
• Verified NFIA as a direct downstream target of miR-223-3p through prediction and experimental validation.

Main Results:

• miR-223-3p mimics significantly downregulated NFIA expression in AC16 cells.
• Knockdown of miR-223-3p attenuated anthracycline-induced apoptosis and autophagy.
• NFIA was confirmed as a direct target of miR-223-3p and its reintroduction rescued cellular functions.
• miR-223-3p exacerbates anthracycline-induced cardiomyocyte damage by targeting NFIA.

Conclusions:

• miR-223-3p plays a critical role in promoting anthracycline-induced cardiomyocyte damage by downregulating NFIA.
• Targeting miR-223-3p presents a promising therapeutic strategy to protect cancer patients from chemotherapy-related heart damage.
• This study provides novel insights into the molecular pathways underlying cardiotoxicity and potential interventions.